GlobeNewsWire
30 Sept 2026, 21:30 UTC · 3h ago
Verdict
Headline takes no side. We score DRUG +0.30 across three claims — moderately bullish.
+0.30moderately bullish
More positive than 63% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Bright Minds Biosciences is conducting a Phase 2a NOVA study of BMB-101 assessing hyperphagia and PWS-associated behaviors over 16 weeks.
Priced inno timing evidence provided for study start
More positive than 80% of claims this week
Bright Minds will participate in the FPWR Research Symposium (Oct 7-8) and PWS Family Conference (Oct 9-10), 2026.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 46% of claims this week
The company entered a mutual rescission agreement to cancel 44,500 common shares previously issued via stock option exercise.
Newannounced today, Sept 30, 2026
So whatThe cancellation of these shares marginally reduces the total shares outstanding, though the impact on EPS is negligible given the small volume.
Near neutral — 98% of claims this week are stronger
Which stocks this story touches
More positive than 63% of ticker scores this week
The company is advancing its clinical program for PWS and participating in a major industry research symposium.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
3h ago
—
DRUG hasn't traded since this ran. Last close $49.82 (Sep 30); the reaction starts at the next open.
DRUG chart →
